Post-marketing evaluation of fertility-regulating drugs, as viewed by regulatory authorities.
D000014:Abnormalities, Drug-Induced / Q000517:prevention & control*; D001530:Belgium; D005069:Evaluation Studies as Topic; D005260:Female; D005299:Fertility Agents / Q000009:adverse effects*; D005860:Germany, West; D006801:Humans; D007558:Italy; D007880:Legislation, Drug; D009426:Netherlands; D011247:Pregnancy; D011358:Product Surveillance, Postmarketing; D013548:Sweden; D006113:United Kingdom; D014481:United States
D005299:Fertility Agents